Retatrutide
Retatrutide: A research peptide acting at three receptors involved in metabolic signalling.
What is it?
A research peptide acting at three receptors involved in metabolic signalling.
How it is studied
Retatrutide activates GIP, GLP-1, and glucagon receptors. Researchers investigate how these overlapping pathways affect energy intake, glucose regulation, and body weight.
What the evidence says
A randomized phase 2 study in adults with obesity reported substantial weight reduction over 48 weeks. Gastrointestinal adverse effects were common, and changes in heart rate were recorded. These findings concern the trial formulation and monitored participants.
What remains uncertain
Clinical research does not establish the identity, safety, or effectiveness of a separately supplied laboratory vial. A receptor mechanism is not a personal treatment recommendation.
Sources & scope
Jastreboff et al., phase 2 obesity trial (2023)
For in-vitro laboratory research only. Not for human or veterinary use.